Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) started the day on May 18, 2021, with a price increase of 4.68% at $4.70. During the day, the stock rose to $4.77 and sunk to $4.45 before settling in for the price of $4.49 at the close. Taking a more long-term approach, ZYNE posted a 52-week range of $3.12-$9.00.
Meanwhile, its Annual Earning per share during the time was 7.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -26.90%. This publicly-traded company’s shares outstanding now amounts to $40.07 million, simultaneously with a float of $28.60 million. The organization now has a market capitalization sitting at $186.54 million. At the time of writing, stock’s 50-day Moving Average stood at $4.52, while the 200-day Moving Average is $4.09.
Zynerba Pharmaceuticals Inc. (ZYNE) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Zynerba Pharmaceuticals Inc.’s current insider ownership accounts for 2.20%, in contrast to 23.20% institutional ownership.
Zynerba Pharmaceuticals Inc. (ZYNE) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 3/31/2021, the organization reported -$0.2 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.25) by $0.05. This company achieved a return on equity of -75.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
Zynerba Pharmaceuticals Inc.’s EPS decrease for this current 12-month fiscal period is -26.90% and is forecasted to reach -1.14 in the upcoming year.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) Trading Performance Indicators
Let’s observe the current performance indicators for Zynerba Pharmaceuticals Inc. (ZYNE). It’s Quick Ratio in the last reported quarter now stands at 8.50. The Stock has managed to achieve an average true range (ATR) of 0.36.
In the same vein, ZYNE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.94, a figure that is expected to reach -0.22 in the next quarter, and analysts are predicting that it will be -1.14 at the market close of one year from today.
Technical Analysis of Zynerba Pharmaceuticals Inc. (ZYNE)
If we take a close look at the recent performances of Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), its last 5-days Average volume was 1.6 million that shows plunge from its year to date volume of 4.14 million. During the previous 9 days, stock’s Stochastic %D was recorded 72.73% While, its Average True Range was 0.37.
Raw Stochastic average of Zynerba Pharmaceuticals Inc. (ZYNE) in the period of the previous 100 days is set at 26.50%, which indicates a major fall in contrast to 89.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 76.11% that was lower than 152.08% volatility it exhibited in the past 100-days period.